A potential therapy for treating COVID-19 by blocking the virus from the neuropilin-1 (NRP1) receptor and inhibiting it from entering cells

An international team has found a way to potentially prevent the novel coronavirus from infecting cells, as well as clues as to why it is more infectious than similar viruses.

 

University of Bristol researchers Dr Yohei Yamauchi and Professor Peter Cullen identified where the virus binds when it is infecting host cells and then joined forces with Dr Kai-En (Kevin) Chen and Professor Brett Collins from IMB to find out more.

 

Putting more pieces of the puzzle together, Dr Chen and Professor Collins were able to show exactly how the virus binds to a host cell by modelling the site where they interact. “The SARS-CoV-2 virus uses a protein called Spike to bind and enter host cells, and we now know that in addition to the already known ACE2 receptor, the Spike binds to a second receptor on the host cells called neuropilin,” Professor Collins said. “We used X-ray crystallography to see the structure of proteins at the atomic level and visualize the binding sites at a spectacular level of detail.”

 

The University of Bristol team then looked at the effect of disrupting the binding between the virus and the second receptor.

"We discovered that by blocking the virus protein from binding neurophilin on the cells, it was possible to reduce the infection rate of the virus," Dr Yamauchi said. “If we can make a drug that blocks the virus from binding to cells, this has potential as a new therapy for treating COVID-19."

Sourced through Scoop.it from: imb.uq.edu.au